{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:55:27Z","timestamp":1772160927698,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006432","name":"Terumo BCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Convalescent plasma (CP) has been embraced as a safe therapeutic option for coronavirus disease 2019 (COVID\u201019), while other treatments are developed. Severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) is not transmissible by transfusion, but bloodborne pathogens remain a risk in regions with high endemic prevalence of disease. Pathogen reduction can mitigate this risk; thus, the objective of this study was to evaluate the effect of riboflavin and ultraviolet light (R\u2009+\u2009UV) pathogen reduction technology on the functional properties of COVID\u201019 CP (CCP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      COVID\u201019 convalescent plasma units (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) from recovered COVID\u201019 research donors were treated with R\u2009+\u2009UV. Pre\u2010 and post\u2010treatment samples were tested for coagulation factor and immunoglobulin retention. Antibody binding to spike protein receptor\u2010binding domain (RBD), S1 and S2 epitopes of SARS\u2010CoV\u20102 was assessed by ELISA. Neutralizing antibody (nAb) function was assessed by pseudovirus reporter viral particle neutralization (RVPN) assay and plaque reduction neutralization test (PRNT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean retention of coagulation factors was \u226570%, while retention of immunoglobulins was 100%. Starting nAb titres were low, but PRNT\n                      <jats:sub>50<\/jats:sub>\n                      titres did not differ between pre\u2010 and post\u2010treatment samples. No statistically significant differences were detected in levels of IgG (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009\u2265\u20090\u00b73665) and IgM (\n                      <jats:italic>P\u2009<\/jats:italic>\n                      \u2265\u20090\u00b71208) antibodies to RBD, S1 and S2 proteins before and after treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>R\u2009+\u2009UV PRT effects on coagulation factors were similar to previous reports, but no significant effects were observed on immunoglobulin concentration and antibody function. SARS\u2010CoV\u20102 nAb function in CCP is conserved following R\u2009+\u2009UV PRT treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.13108","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T07:34:21Z","timestamp":1617953661000},"page":"1076-1083","source":"Crossref","is-referenced-by-count":10,"title":["Preservation of neutralizing antibody function in COVID\u201019 convalescent plasma treated using a riboflavin and ultraviolet light\u2010based pathogen reduction technology"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7987","authenticated-orcid":false,"given":"Susan","family":"Yonemura","sequence":"first","affiliation":[{"name":"Terumo Blood and Cell Technologies Lakewood CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3507","authenticated-orcid":false,"given":"Lindsay","family":"Hartson","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Center Colorado State University Fort Collins CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-1311","authenticated-orcid":false,"given":"Taru S.","family":"Dutt","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology &amp; Pathology Colorado State University Fort Collins CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-9650","authenticated-orcid":false,"given":"Marcela","family":"Henao\u2010Tamayo","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology &amp; Pathology Colorado State University Fort Collins CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-4571","authenticated-orcid":false,"given":"Raymond","family":"Goodrich","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Center Colorado State University Fort Collins CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7862-6201","authenticated-orcid":false,"given":"Susanne","family":"Marschner","sequence":"additional","affiliation":[{"name":"Terumo Blood and Cell Technologies Lakewood CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-8-200610170-00139"},{"key":"e_1_2_11_3_1","first-page":"199","article-title":"Treatment of severe acute respiratory syndrome with convalescent plasma","volume":"9","author":"Wong VW","year":"2003","journal-title":"Hong Kong Med J"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki346"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3243"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq106"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1609116"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.028"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893"},{"key":"e_1_2_11_12_1","unstructured":"FDA.COVID\u201019 Frequently Asked Questions.https:\/\/www.fda.gov\/emergency\u2010preparedness\u2010and\u2010response\/coronavirus\u2010disease\u20102019\u2010covid\u201019\/covid\u201019\u2010frequently\u2010asked\u2010questions#biologics. [Last accessed 10 Nov 2020]."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12939"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2014.12.016"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15344"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/php.12311"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12937"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233947"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01238.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18468-8"},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","unstructured":"Goodhue MeyerE SimmonsG GrebeE et\u00a0al.Selecting COVID\u201019 convalescent plasma for neutralizing antibody potency using a high\u2010capacity SARS\u2010CoV\u20102 antibody assay. medRxiv2020.","DOI":"10.1101\/2020.08.31.20184895"},{"key":"e_1_2_11_23_1","volume-title":"Guide to the preparation, use and quality assurance of blood components","author":"EDQM","year":"2020"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02517.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2009.09.006"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02272.x"},{"key":"e_1_2_11_27_1","first-page":"25","article-title":"Protein stability of previously frozen plasma, riboflavin and UV light\u2010treated, refrozen and stored for up to 2 years at\u2212 30\u00b0 C","volume":"44","author":"Ettinger A","year":"2011","journal-title":"Transfusion"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.moh.0000137915.88478.23"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00483.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12697"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2008.001147.x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13393"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15739"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2571-7"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ680"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.15-0890"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.11.009"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12047"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12048"},{"key":"e_1_2_11_40_1","unstructured":"FDA.Clinical Memorandum Re: EUA 26382: Emergency Use Authorization (EUA) Request.https:\/\/www.fda.gov\/media\/141480\/download. [Last accessed 10 Nov 2020]."},{"key":"e_1_2_11_41_1","unstructured":"FDA.Revised EUA for Use of COVID\u201019 Convalescent Plasma (March 9 2021).https:\/\/www.fda.gov\/media\/141477\/download. [Last accessed 11 March 2021]."}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.13108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:25:56Z","timestamp":1693225556000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/vox.13108"],"URL":"https:\/\/doi.org\/10.1111\/vox.13108","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.18.21251437","asserted-by":"object"}]},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]}}}